scholarly journals Marital Status Independently Predicts Survival in Patients with Small Cell Lung Cancer: A SEER Database Analysis

2021 ◽  
Author(s):  
Pei Luo ◽  
Yan Mao ◽  
Liping Yang ◽  
Chao Pan ◽  
Jun Guo
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Marital Status ◽  
Cell Lung Cancer ◽  
Cox Regression ◽  
Small Cell ◽  
Rank Test ◽  
Seer Database ◽  
Small Cell Lung ◽  
Kaplan Meier

Abstract Purpose This study will investigate the relationship between marital status and prognosis in small cell lung cancer patients. Methods Patients of SCLC was selected from the SEER database (1973-2013) and the patient sinformation. Kaplan-Meier analysis, log-rank test and Cox regression model were used for studying patientprognosis. Result 27069 SCLC patients eligible for inclusion were screened from the SEER database. Kaplan-meier test showed that the median OS values were 8, 7, 6 months in married, single and SDW patients, respectively. Conclusion This study shows that marital status is an independent prognostic factor for overall survival in SCLC patients. Married patients with small cell lung cancer have better prognosis than those who were divorced/separated, widowed and single.

Preoperative serum CA125 as an independent predictor for recurrence and death in operable patients with non-small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18520-e18520
Author(s):  
Jianguo Feng ◽  
Haiyan Xu ◽  
Hanmo Wu ◽  
Min Luo ◽  
Weimin Mao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Kaplan Meier ◽  
Preoperative Serum ◽  
Serum Ca125

e18520 Background: The role of serum CA125 in the prognosis of non-small cell lung cancer (NSCLC) remains controversial, especially in early stage patients. The aim of this study is to analyze the prognostic value of CA125 in operable NSCLC. Methods: We retrospectively analyzed 645 patients with non-small cell lung cancer (NSCLC) who underwent curative surgical resection for lung cancer at Zhejiang Cancer Hospital of China from 2006 to 2011. Micropartical enzyme immunoassay was used to measure preoperative serum CA125. Pearson’s chi test was used in univariate analyses and a multivariable proportional hazard Cox regression model was applied to assess the prognostic significance of the different covariates. Kaplan-Meier was used to analyze survival curve. Results: The positive rate of preoperative serum CA125 was 18.9% (126/667) in all patients, and elevated CA125 concentration was associated to poorly differentiated tumor and advanced clinical stage. Moreover, CA125 was closely related to patient outcomes. The Kaplan-Meier survival curves were shown patient with normal CA125 concentration had significantly longer DFS (median DFS, not reach vs 21 months, p=0.000) and OS (median OS, 61 vs 29 months, p=0.000) than those with positive CA125. Multivariate Cox analysis indicated patients with positive CA125 had an elevated risk of disease recurrence or death compared with those who had negative one. The adjusted hazard ratio (HR) was 1.74 for replase (95% confidence interval [CI], 1.25-2.41, p=0.001) and 1.79 for death (95% CI, 1.34-2.41, p=0.000) after adjusted by age, gender, grade, stage, histology and smoking status. Conclusions: CA125 seems to play an important role in disease progression and it may be an independent predictive marker for prognosis in patients with NSCLC. [Table: see text]

Efficacy and toxicity hypofractionated radiotherapy for centrally located non-small cell lung cancer

2021 ◽  
pp. 1-4
Author(s):  
Tanzeel Janjua ◽  
Fei Sun ◽  
Katy Clarke ◽  
Pete Dickinson ◽  
Kevin Franks ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cox Regression ◽  
Early Stage ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
Early Stage Lung Cancer ◽  
Cox Regression Analysis

Abstract Aim: Centrally located early-stage non-small cell lung cancer in patients who are unfit for surgery are treated with fractionated radiotherapy. We present the outcomes of a moderately hypofractionated accelerated dose regimen of 50 Gy in 15 fractions from a single centre in the UK. Materials and methods: Electronic case notes and radiotherapy records of lung cancer patients treated between January 2014 and December 2016 were retrospectively reviewed. Adult Comorbidity Evaluation-27 score was used to evaluate comorbidities. Mean lung doses and percentage of lung receiving more than 20 Gy were calculated for all patients. Survival outcomes were estimated using Kaplan–Meier curves. Results: Fifty-three patients were included in the study; the median follow-up was 20.2 months. 87% of patients had stage I disease. There was no 30-day post-treatment mortality. Ninety-day mortality rate after radiotherapy was 3.8%. Grade 2 pneumonitis was seen in five patients while no grade 3 or 4 pneumonitis was observed. The median progression-free survival (PFS) and overall survival (OS) were 18.5 months and 28.2 months, respectively. The estimated 1 and 2 years PFS were 62.3% and 41.3%, respectively, and OS were 77.4% and 56.6%, respectively. Worsening performance status was associated with worse survival on cox regression analysis. Disease relapsed in 36% of patients. 7.5% of patients with relapsed disease had infield recurrence. Findings: 50 Gy in 15 fractions radiotherapy for central early-stage lung cancer is a feasible choice that requires further randomised trials.

Sign in / Sign up

Export Citation Format

Share Document